Handelsbanken Fonder
MLYS icon

Handelsbanken Fonder’s Mineralys Therapeutics MLYS Stock Holding History

Handelsbanken Fonder’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$734K Buy
27,200
+13,100
+93% +$359K ﹤0.01% 1263
2026
Q1 		$382K Hold
14,100
– – ﹤0.01% 1366
2025
Q4 		$512K Buy
+14,100
New +$565K ﹤0.01% 1298

Other funds holding MLYS

AP
Andera Partners Paris $206M AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Handelsbanken Fonder's MLYS Position: Q2 2026 in Review

Handelsbanken Fonder increased its Mineralys Therapeutics (MLYS) stake by 93% in Q2 2026, buying an estimated $359K and bringing the position to 27,200 shares worth $734K. The position accounts for ﹤0.01% of the portfolio, ranked #1263.

Handelsbanken Fonder first reported a position in MLYS in Q4 2025 and has held it in 3 quarters since. 32 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Handelsbanken Fonder held 27,200 shares of Mineralys Therapeutics worth $734K as of Q2 2026.
  • Handelsbanken Fonder bought 13,100 Mineralys Therapeutics shares in Q2 2026, an estimated $359K.
  • Mineralys Therapeutics made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #1263 holding.
  • Handelsbanken Fonder first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 32 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.